Keywords: gsk, gets, ok, return, lotronex, irritable, bowel
GSK gets OK to return Lotronex to US irritable bowel syndrome market
Article | 17 June 2002
GlaxoSmithKline has been given the go-ahead by the US Food and DrugAdministration to re-introduce its irritable bowel syndrome drug Lotronex ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
